Genmab — Maj 2021

[kkjoel]

Jeps, Helge. Vil huske at kigge der først

[nohope]

Hvis det er et lønligt håb - så skal han vel ikke stå og kæfte op om det ?

[nohope]

GEN er nu faldet 70 kr. i forhold til åbningskursen - og US er end ikke åbent endnu.

[Vitus]

Der er vel god grund til at være skuffet over kursreaktionen i dag, men så længe vildgiftssagen ligger som en dyne over Genmab, vil kursen ikke ændre sig væsentligt i forhold til nu....skal nok også ses i sammenhæng med manglende opjustering på baggrund af det flotte Q1. Kursudvikling og superlativer hænger ikke sammen.....

[Riis7]

Den ender nok i minus når us åbner:-)

[kkjoel]

Nej, men det kan du jo sige til ham, nohope. Good luck.

[nohope]

-næste gang jeg ser ham på den lokale bodega, skal jeg nok sige det.

[Vitus]

Når nu en voldgift har til formål at afslutte en tvist betydeligt hurtigere end en retssag, kan vi vel forvente en snarlig afgørelse....

[Bulder]

Novod på banen igen. Han anslår amivantamab peaksale $ 1,1 mia i den oprindelige indikation, som er meget lille. Winkel talte i går om at udvide indikationen til at omfatte 20% af al lungecancer. Hvis vi siger 10% til genmab, så kan man selv regne lidt på det.

[Bulder]

Winkel i går: But if actually that larger population would read out positively then the income profile is quite substantial.

[E_L]

what does Novod mean with the 'den oprindelige indikation'; does he mean only that smaller EGFR Exon 20 mutations population?

[E_L]

i see he also lifts peak Dara sales to $12.5bn from $10bn

[Bulder]

Yes, as Winkel also said: As we both know, the initial population in lung cancer is quite small. It's a subset of patients and a very small subset. I assume he's talking about exon20

[E_L]

ok, thanks. I wasn't sure that part on it's own was gonna be valued that much already by the analysts, so good to see
.

[E_L]

I have had high expectations for a long time for this. Jan seemed to think a summer approval is a possibility. Would be a nice holiday-news item.

[E_L]

On HexaCD38, there has always been some doubt in the back of my mind whether JNJ can really hold off their opt-in if results are really really good.

[E_L]

Suppose there is a clear and demonstrably large outperformance by HexaCD38 over Dara but JNJ has still not pulled the trigger; what will the market say? Patients and doctors? Can you deny them a drug that is really much better?

[Sukkeralf]

As NSCLC is such a big indikation - you could as always hope for some off label sales if we get an approval mid year

[Sukkeralf]

E L I think they can´t do that - i would guess the rights fall back to Genmab and that is written in the contract. Kind of mismanagement from Janssen

[Sukkeralf]

But that could be a good quenstion for Jan at the next Q&A